Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report

G. Schifitto, D. R. Peterson, J. Zhong, H. Ni, K. Cruttenden, M. Gaugh, Howard Eliot Gendelman, M. Boska, H. Gelbard

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.

Original languageEnglish (US)
Pages (from-to)919-921
Number of pages3
JournalNeurology
Volume66
Issue number6
DOIs
StatePublished - Mar 1 2006

Fingerprint

Valproic Acid
HIV
Therapeutics
Animal Models
Placebos
Brain
Cognitive Dysfunction

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Schifitto, G., Peterson, D. R., Zhong, J., Ni, H., Cruttenden, K., Gaugh, M., ... Gelbard, H. (2006). Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report. Neurology, 66(6), 919-921. https://doi.org/10.1212/01.wnl.0000204294.28189.03

Valproic acid adjunctive therapy for HIV-associated cognitive impairment : A first report. / Schifitto, G.; Peterson, D. R.; Zhong, J.; Ni, H.; Cruttenden, K.; Gaugh, M.; Gendelman, Howard Eliot; Boska, M.; Gelbard, H.

In: Neurology, Vol. 66, No. 6, 01.03.2006, p. 919-921.

Research output: Contribution to journalArticle

Schifitto, G, Peterson, DR, Zhong, J, Ni, H, Cruttenden, K, Gaugh, M, Gendelman, HE, Boska, M & Gelbard, H 2006, 'Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report', Neurology, vol. 66, no. 6, pp. 919-921. https://doi.org/10.1212/01.wnl.0000204294.28189.03
Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report. Neurology. 2006 Mar 1;66(6):919-921. https://doi.org/10.1212/01.wnl.0000204294.28189.03
Schifitto, G. ; Peterson, D. R. ; Zhong, J. ; Ni, H. ; Cruttenden, K. ; Gaugh, M. ; Gendelman, Howard Eliot ; Boska, M. ; Gelbard, H. / Valproic acid adjunctive therapy for HIV-associated cognitive impairment : A first report. In: Neurology. 2006 ; Vol. 66, No. 6. pp. 919-921.
@article{7128eecc5b444934be4e9440af3b36aa,
title = "Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report",
abstract = "In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.",
author = "G. Schifitto and Peterson, {D. R.} and J. Zhong and H. Ni and K. Cruttenden and M. Gaugh and Gendelman, {Howard Eliot} and M. Boska and H. Gelbard",
year = "2006",
month = "3",
day = "1",
doi = "10.1212/01.wnl.0000204294.28189.03",
language = "English (US)",
volume = "66",
pages = "919--921",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Valproic acid adjunctive therapy for HIV-associated cognitive impairment

T2 - A first report

AU - Schifitto, G.

AU - Peterson, D. R.

AU - Zhong, J.

AU - Ni, H.

AU - Cruttenden, K.

AU - Gaugh, M.

AU - Gendelman, Howard Eliot

AU - Boska, M.

AU - Gelbard, H.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.

AB - In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.

UR - http://www.scopus.com/inward/record.url?scp=33645837210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645837210&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000204294.28189.03

DO - 10.1212/01.wnl.0000204294.28189.03

M3 - Article

C2 - 16510768

AN - SCOPUS:33645837210

VL - 66

SP - 919

EP - 921

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -